Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Operating Margin (2016 - 2025)

Bioadaptives' Operating Margin history spans 7 years, with the latest figure at 2379.56% for Q4 2025.

  • On a quarterly basis, Operating Margin changed N/A to 2379.56% in Q4 2025 year-over-year; TTM through Dec 2025 was 5701.79%, a 94932.0% decrease, with the full-year FY2025 number at 5701.79%, down 94932.0% from a year prior.
  • Operating Margin hit 2379.56% in Q4 2025 for Bioadaptives, up from 5735.95% in the prior quarter.
  • Over the last five years, Operating Margin for BDPT hit a ceiling of 415.47% in Q1 2024 and a floor of 13774.52% in Q2 2024.
  • Historically, Operating Margin has averaged 3447.4% across 5 years, with a median of 2392.01% in 2023.
  • Biggest five-year swings in Operating Margin: crashed -1138251bps in 2024 and later surged 510043bps in 2025.
  • Tracing BDPT's Operating Margin over 5 years: stood at 4615.27% in 2021, then skyrocketed by 85bps to 685.29% in 2022, then fell by -25bps to 857.99% in 2023, then crashed by -1505bps to 13774.52% in 2024, then surged by 83bps to 2379.56% in 2025.
  • Business Quant data shows Operating Margin for BDPT at 2379.56% in Q4 2025, 5735.95% in Q3 2025, and 8674.09% in Q2 2025.